Dapagliflozin in patients with type 2 diabetes mellitus.
Filippatos TD, Liberopoulos EN, Elisaf MS.
Ther Adv Endocrinol Metab · review-article; review; journal article · DOI 10.1177/2042018814558243 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för dapagliflozin. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
47 hitsSodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Powell J, Miller SA, Taylor JR.
South Med J · review; journal article · DOI 10.14423/smj.0000000000000233Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Mikhail N.
South Med J · review; journal article · DOI 10.14423/smj.0000000000000235[Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
Sanz-Serra P, Pedro-Botet J, Flores-Le Roux JA, Benaiges D, Chillarón JJ.
Clin Investig Arterioscler · review; journal article · DOI 10.1016/j.arteri.2014.11.001Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
Davis PN, Ndefo UA, Oliver A.
J Pharm Pract · review; journal article · DOI 10.1177/0897190014566308Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study 05 Group.
Diabetes Care · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.2337/dc14-0666Dapagliflozin: drug profile and its role in individualized treatment.
Sposetti G, MacKinnon I, Barengo NC.
Expert Rev Cardiovasc Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1586/14779072.2015.995636Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, Rothenberg P, Plum-Mörschel L.
Diabetes Obes Metab · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1111/dom.12418Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
Cai W, Jiang L, Xie Y, Liu Y, Liu W, Zhao G.
Med Chem · historical article; research support, non-u.s. gov't; review; journal article · DOI 10.2174/1573406411666150105105529Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.
Rizzo M, Al-Busaidi N, Rizvi AA.
Expert Opin Pharmacother · research support, non-u.s. gov't; editorial · DOI 10.1517/14656566.2015.981528Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
Parikh S, Wilding J, Jabbour S, Hardy E.
Int J Clin Pract · research support, non-u.s. gov't; journal article · DOI 10.1111/ijcp.12531Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
Maranghi M, Carnovale A, Durante C, Tarquini G, Tiseo G, Filetti S.
Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2015.986457Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats.
Hamouda NN, Sydorenko V, Qureshi MA, Alkaabi JM, Oz M, Howarth FC.
Mol Cell Biochem · research support, non-u.s. gov't; journal article · DOI 10.1007/s11010-014-2262-5Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Schumm-Draeger PM, Burgess L, Korányi L, Hruba V, Hamer-Maansson JE, de Bruin TW.
Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/dom.12387Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Sabale U, Ekman M, Granström O, Bergenheim K, McEwan P.
Prim Care Diabetes · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.pcd.2014.04.007Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM, White JR.
Drugs Today (Barc) · journal article · DOI 10.1358/dot.2013.49.5.1964714Dapagliflozin: BMS 512148; BMS-512148.
Författaruppgift saknas
Drugs R D · research-article; review; journal article · DOI 10.2165/11537740-000000000-00000